The Community Guide

- gsearch

Search Results

Narrow Results:

2021 3
2019 1
2014 2
2013 1
2011 1

Journal Article 8

1 - 8 of 8 Results

Refine Results

Refine Results:

Epidemic Cholera in a Crowded Urban Environment, Port-au-Prince, Haiti

CITE Title : Epidemic Cholera in a Crowded Urban Environment, Port-au-Prince, Haiti Personal Author(s) : Dunkle, Stacie E.;Mba-Jonas, Adamma;Loharikar, Anagha;Fouché, Bernadette;Peck, Mireille;Ayers, Tracy;Archer, W. Roodly;De Rochars, Valery M. Beau;Bender, Thomas;Moffett, Daphne B.;Tappero, Jordan W.;Dahourou, George;Roels, Thierry H.;Quick, Robert; Published Date : Nov 2011 Source : Emerg Infect Dis. 17(11):2143-2146. URL : https://stacks.cdc.gov/view/cdc/23733 Dunkle, Stacie E. et al. (2011). Epidemic Cholera in a Crowded Urban Environment, Port-au-Prince, Haiti. 17(11). Dunkle, Stacie E. et al. "Epidemic Cholera in a Crowded Urban Environment, Port-au-Prince, Haiti" 17, no. 11 (2011) Dunkle, Stacie E. et al. "Epidemic Cholera in a Crowded Urban Environment, Port-au-Prince, Haiti" vol. 17, no. 11, 2011 Export RIS Citation Information.

:

Dunkle, Stacie E. ;

Mba-Jonas, Adamma

Nov 2011 | Emerg Infect Dis. 17(11):2143-2146.

:

We conducted a case-control study to investigate factors associated with epidemic cholera. Water treatment and handwashing may have been protective, h...
Safety of the 9-Valent Human Papillomavirus Vaccine

CITE Title : Safety of the 9-Valent Human Papillomavirus Vaccine Personal Author(s) : Shimabukuro, Tom T.;Su, John R.;Marquez, Paige L.;Mba-Jonas, Adamma;Arana, Jorge E.;Cano, Maria V.; Published Date : 12 2019;12-2019; Source : Pediatrics. 144(6) URL : https://stacks.cdc.gov/view/cdc/83849 Shimabukuro, Tom T. et al. (2019). Safety of the 9-Valent Human Papillomavirus Vaccine. 144(6). Shimabukuro, Tom T. et al. "Safety of the 9-Valent Human Papillomavirus Vaccine" 144, no. 6 (2019) Shimabukuro, Tom T. et al. "Safety of the 9-Valent Human Papillomavirus Vaccine" vol. 144, no. 6, 2019 Export RIS Citation Information.

:

Shimabukuro, Tom T. ;

Su, John R.

12 2019 | Pediatrics. 144(6)

:

BACKGROUND:The 9-valent human papillomavirus vaccine (9vHPV) was approved for females and males aged 9 to 26 years in 2014. We analyzed postlicensure ...
Outreach to Underserved Communities in Northern Nigeria, 2012–2013

CITE Title : Outreach to Underserved Communities in Northern Nigeria, 2012–2013 Personal Author(s) : Gidado, Saheed O.;Ohuabunwo, Chima;Nguku, Patrick M.;Ogbuanu, Ikechukwu U.;Waziri, Ndadilnasiya E.;Biya, Oladayo;Wiesen, Eric S.;Mba-Jonas, Adamma;Vertefeuille, John;Oyemakinde, Akin;Nwanyanwu, Okey;Lawal, Namadi;Mahmud, Mustapha;Nasidi, Abdulsalami;Mahoney, Frank J.; Corporate Authors(s) : N-STOP Outreach Team Published Date : 11 01 2014;11-01-; Source : J Infect Dis. 210(Suppl 1):S118-S124 URL : https://stacks.cdc.gov/view/cdc/133852 Gidado, Saheed O. et al. (2014). Outreach to Underserved Communities in Northern Nigeria, 2012–2013. 210 Gidado, Saheed O. et al. "Outreach to Underserved Communities in Northern Nigeria, 2012–2013" 210 (2014) Gidado, Saheed O. et al. "Outreach to Underserved Communities in Northern Nigeria, 2012–2013" vol. 210, 2014 Export RIS Citation Information.

:

Gidado, Saheed O. ;

Ohuabunwo, Chima

11 01 2014 | J Infect Dis. 210(Suppl 1):S118-S124

:

Background.Persistent wild poliovirus transmission in Nigeria constitutes a major obstacle to global polio eradication. In August 2012, the Nigerian n...
Treatment and Outcomes among Patients with Cryptococcus gattii Infections in the United States Pacific Northwest

CITE Title : Treatment and Outcomes among Patients with Cryptococcus gattii Infections in the United States Pacific Northwest Personal Author(s) : Smith, Rachel M.;Mba-Jonas, Adamma;Tourdjman, Mathieu;Schimek, Trisha;DeBess, Emilio;Marsden-Haug, Nicola;Harris, Julie R.; Published Date : Feb 19 2014 Source : PLoS One. 2014; 9(2). URL : https://stacks.cdc.gov/view/cdc/27827 Smith, Rachel M. et al. (2014). Treatment and Outcomes among Patients with Cryptococcus gattii Infections in the United States Pacific Northwest. 9(2). Smith, Rachel M. et al. "Treatment and Outcomes among Patients with Cryptococcus gattii Infections in the United States Pacific Northwest" 9, no. 2 (2014) Smith, Rachel M. et al. "Treatment and Outcomes among Patients with Cryptococcus gattii Infections in the United States Pacific Northwest" vol. 9, no. 2, 2014 Export RIS Citation Information.

:

Smith, Rachel M. ;

Mba-Jonas, Adamma

Feb 19 2014 | PLoS One. 2014; 9(2).

:

BackgroundCryptococcus gattii is a fungal pathogen causing an emerging outbreak in the United States Pacific Northwest (PNW). Treatment guidelines for...
Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons

CITE Title : Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons Personal Author(s) : Shimabukuro, Tom T.;Kim, Shin Y.;Myers, Tanya R.;Moro, Pedro L.;Oduyebo, Titilope;Panagiotakopoulos, Lakshmi;Marquez, Paige L.;Olson, Christine K.;Liu, Ruiling;Chang, Karen T.;Ellington, Sascha R.;Burkel, Veronica K.;Smoots, Ashley N.;Green, Caitlin J.;Licata, Charles;Zhang, Bicheng C.;Alimchandani, Meghna;Mba-Jonas, Adamma;Martin, Stacey W.;Gee, Julianne M.;Meaney-Delman, Dana M.; Published Date : June 17 2021 Source : N Engl J Med. 2021; URL : https://stacks.cdc.gov/view/cdc/106333 Shimabukuro, Tom T. et al. (2021). Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons. Shimabukuro, Tom T. et al. "Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons" (2021) Shimabukuro, Tom T. et al. "Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons" , 2021 Export RIS Citation Information.

:

Shimabukuro, Tom T. ;

Kim, Shin Y.

June 17 2021 | N Engl J Med. 2021;

:

BackgroundMany pregnant persons in the United States are receiving messenger RNA (mRNA) coronavirus disease 2019 (Covid-19) vaccines, but data are lim...
Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices — United States, July 2021

CITE Title : Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices — United States, July 2021 Personal Author(s) : Rosenblum, Hannah G.;Hadler, Stephen C.;Moulia, Danielle;Shimabukuro, Tom T.;Su, John R.;Tepper, Naomi K.;Ess, Kevin C.;Woo, Emily Jane;Mba-Jonas, Adamma;Alimchandani, Meghna;Nair, Narayan;Klein, Nicola P.;Hanson, Kayla E.;Markowitz, Lauri E.;Wharton, Melinda;McNally, Veronica V.;Romero, José R.;Talbot, H. Keipp;Lee, Grace M.;Daley, Matthew F.;Mbaeyi, Sarah A.;Oliver, Sara E.; Published Date : 8 13 2021 Pages in Document : 6 pdf pages Series : Weekly Report: Morbidity and Mortality Weekly Report (MMWR) Source : MMWR Morbidity Mortal Weekly Rep. 70(32):1094-1099 DOI : http://dx.doi.org/10.15585/mmwr.mm7032e4 Journal Title : Morbidity and Mortality Weekly Report (MMWR) Rosenblum, Hannah G. et al. (2021). Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices — United States, July 2021. 70(32). http://dx.doi.org/10.15585/mmwr.mm7032e4 Rosenblum, Hannah G. et al. "Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices — United States, July 2021" 70, no. 32 (2021), http://dx.doi.org/10.15585/mmwr.mm7032e4 Rosenblum, Hannah G. et al. "Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices — United States, July 2021" vol. 70, no. 32, 2021, http://dx.doi.org/10.15585/mmwr.mm7032e4 Export RIS Citation Information.

:

Rosenblum, Hannah G. ;

Hadler, Stephen C.

8 13 2021 | Weekly Report: Morbidity and Mortality Weekly Report (MMWR)

:

In December 2020, the Food and Drug Administration (FDA) issued Emergency Use Authorizations (EUAs) for Pfizer-BioNTech and Moderna Covid-19 Vaccines,...
Outbreak of Escherichia coli O104:H4 Infections Associated with Sprout Consumption — Europe and North America, May–July 2011

CITE Title : Outbreak of Escherichia coli O104:H4 Infections Associated with Sprout Consumption — Europe and North America, May–July 2011 Personal Author(s) : Foley, Catherine;Harvey, Emily;Bidol, Sally A.;Henderson, Tiffany;Njord, Rebecca;DeSalvo, Traci;Haupt, Thomas;Mba-Jonas, Adamma;Bailey, Chris;Bopp, Cheryl;Bosch, Stacey A.;Gerner-Smidt, Peter;Mody, Rajal K.;Nguyen, Thai-An;Strockbine, Nancy;Tauxe, Robert V.; Published Date : Dec 20 2013 Pages in Document : 3 pdf pages Series : Weekly Report: Morbidity and Mortality Weekly Report (MMWR) Source : MMWR Morbidity Mortal Weekly Rep. 2013; 62(50):1029-1031. URL : https://stacks.cdc.gov/view/cdc/54788 Journal Title : Morbidity and Mortality Weekly Report (MMWR) Foley, Catherine et al. (2013). Outbreak of Escherichia coli O104:H4 Infections Associated with Sprout Consumption — Europe and North America, May–July 2011. 62(50). Foley, Catherine et al. "Outbreak of Escherichia coli O104:H4 Infections Associated with Sprout Consumption — Europe and North America, May–July 2011" 62, no. 50 (2013) Foley, Catherine et al. "Outbreak of Escherichia coli O104:H4 Infections Associated with Sprout Consumption — Europe and North America, May–July 2011" vol. 62, no. 50, 2013 Export RIS Citation Information.

:

Foley, Catherine ;

Harvey, Emily

Dec 20 2013 | Weekly Report: Morbidity and Mortality Weekly Report (MMWR)

:

In May 2011, public health authorities in Europe began investigating an outbreak of Shiga toxin-producing Escherichia coli (STEC) O104:H4 infections t...
Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and MRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update From the Advisory Committee on Immunization Practices — United States, July 2021

CITE Title : Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and MRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update From the Advisory Committee on Immunization Practices — United States, July 2021 Personal Author(s) : Rosenblum, Hannah G.;Hadler, Stephen C.;Moulia, Danielle;Shimabukuro, Tom T.;Su, John R.;Tepper, Naomi K.;Ess, Kevin C.;Woo, Emily Jane;Mba-Jonas, Adamma;Alimchandani, Meghna;Nair, Narayan;Klein, Nicola P.;Hanson, Kayla E.;Markowitz, Lauri E.;Wharton, Melinda;McNally, Veronica V.;Romero, José R.;Talbot, H. Keipp;Lee, Grace M.;Daley, Matthew F.;Mbaeyi, Sarah A.;Oliver, Sara E.; Corporate Authors(s) : United States. Advisory Committee on Immunization Practices.;CDC COVID-19 Response Team.;Centers for Disease Control and Prevention (U.S.). Epidemic Intelligence Service.;Vanderbilt University School of Medicine.;United States. Food and Drug Administration.;Kaiser Permanente Northern California. Division of Research.;Marshfield Clinic Research Institute.;Franny Strong Foundation (West Bloomfield, Michigan);Arkansas. Department of Arkansas. Department of Health.;Stanford University School of Medicine.;Kaiser Permanente Colorado. Institute for Health Research.; Published Date : August 10, 2021 Pages in Document : 7 pdf pages Series : Weekly Report: Morbidity and Mortality Weekly Report (MMWR) Source : MMWR: Morbidity and Mortality Weekly Report 2021; v. 70 Early Release URL : https://stacks.cdc.gov/view/cdc/108729 Rosenblum, Hannah G. et al. (2021). Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and MRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update From the Advisory Committee on Immunization Practices — United States, July 2021. 70 Rosenblum, Hannah G. et al. "Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and MRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update From the Advisory Committee on Immunization Practices — United States, July 2021" 70 (2021) Rosenblum, Hannah G. et al. "Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and MRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update From the Advisory Committee on Immunization Practices — United States, July 2021" vol. 70, 2021 Export RIS Citation Information.

:

Rosenblum, Hannah G. ;

Hadler, Stephen C.

August 10, 2021 | Weekly Report: Morbidity and Mortality Weekly Report (MMWR)

:

What is already known about this topic? Rare serious adverse events have been reported after COVID-19 vaccination, including Guillain-Barré syndrome ...